INmune Bio Reports Q3 2026 Net Loss of $4.7 Million and Outlines Regulatory Path for Ebstracel
INmune Bio (INMB) reported its third-quarter 2026 financial results, showing a net loss of $4.7 million, an improvement from the $6.5 million loss recorded in the prior year. This reduction was driven by lower research and development and general administrative expenses. The company maintains a cash position of $16.3 million, which management expects to fund operations through the third quarter of 2027. The company is pivoting toward commercialization for its lead candidate, Ebstracel, targeting recessive dystrophic epidermolysis bullosa (RDEB). INmune Bio has revised its strategy in the United Kingdom to potentially accelerate approval by 6 to 12 weeks, with a submission targeted for early February 2027. In the U.S., a Biologics License Application (BLA) is planned for mid-2027 following an upcoming FDA meeting.
Topics: cash runway earnings report equity offering net loss regulatory approval